The mechanism of action is based on inhibiting the phosphorylation of tumor-suppressor retinoblastoma protein by preventing CDK4/6 from binding to cyclin D. This effectively inhibits tumor cell proliferation, and delay or even overcome the development of endocrine resistance. The gene discussed is CDK4; the disease is neoplasm.